Published in South Med J on October 01, 1997
Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextran-treated mice. Infect Immun (2000) 1.42
Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun (2002) 1.37
Clinical manifestation and prognostic factors of non-cholerae Vibrio infections. Eur J Clin Microbiol Infect Dis (2011) 0.97
Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol (2016) 0.83
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
The regulator HlyU, the repeat-in-toxin gene rtxA1, and their roles in the pathogenesis of Vibrio vulnificus infections. Microbiologyopen (2012) 0.80
Vibrio vulnificus DNA load and mortality. J Clin Microbiol (2010) 0.80
PBHMDA: Path-Based Human Microbe-Disease Association Prediction. Front Microbiol (2017) 0.77
Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms. Infect Immun (2014) 0.75
Medical Care of the Patient With Compensated Cirrhosis. Gastroenterol Hepatol (N Y) (2006) 0.75
Alfentanil for conscious sedation during colonoscopy. South Med J (1995) 2.07
An open-label study of chronic polyethylene glycol laxative use in chronic constipation. Aliment Pharmacol Ther (2007) 1.57
Analysis of sweet diterpene glycosides from Stevia rebaudiana: improved HPLC method. J Agric Food Chem (2001) 1.37
Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol (1994) 1.04
Successful streptokinase therapy of acute idiopathic superior vena cava thrombosis. Am Heart J (1981) 0.91
Cytogenetic and clinical findings in ten 45,X/46,XY patients. Clin Genet (1984) 0.90
Management of ascites. Paracentesis as a guide. Postgrad Med (1997) 0.87
Local versus global interactions in nonequilibrium transitions: A model of social dynamics. Phys Rev E Stat Nonlin Soft Matter Phys (2006) 0.85
Cytomegalovirus hepatitis mimicking an acute exacerbation of chronic hepatitis B. South Med J (1996) 0.80
Immune globulin and vaccine therapy to prevent hepatitis A infection. Am J Med (1998) 0.78
Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report. Arch Neurol (1981) 0.77
Occupational and industrial toxin exposures and the gastrointestinal tract. Gastrointestinal Toxicology Subcommittee of the American College of Gastroenterology Patient Care Committee. Am J Gastroenterol (1991) 0.76
Patient positioning during colonoscopy. Gastrointest Endosc (1992) 0.75
[Cortical and trabecular bone lesions in insulin-dependent diabetes mellitus]. Rev Clin Esp (1991) 0.75
Management of ascites. Compr Ther (1995) 0.75
Is a Hemoccult-positive rectal examination clinically significant? South Med J (1993) 0.75
Should nitrates be used with beta blockers to prevent variceal bleeding? Am J Gastroenterol (2000) 0.75
[A case of pituitary gigantism]. Rev Clin Esp (1968) 0.75
[Our experience with Daonil. A new oral hypoglycemic agent]. Diabete (1970) 0.75
[The response of cortisol to depot synthetic ACTH stimulation]. Rev Clin Esp (1972) 0.75
Chronic hepatitis C: implications for the primary care clinician. JAAPA (2001) 0.75
Influence of the oceanographic conditions during spring 2003 on the transport of the Prestige tanker fuel oil to the Galician coast. Mar Pollut Bull (2005) 0.75
Colorectal cancer screening: is one-year surveillance sigmoidoscopy necessary? Am J Gastroenterol (1993) 0.75
Total volume paracentesis: a new approach to variceal bleeding? Am J Gastroenterol (1997) 0.75
[Personal experience on the use of glybenclamide (a new oral hypoglycemic agent)]. Rev Clin Esp (1970) 0.75
Can postoperative relapse of Crohn's disease be prevented? Am J Gastroenterol (2001) 0.75
[Mixed gonadal dysgenesia. Findings on a case report]. Rev Clin Esp (1968) 0.75
Biliary cystadenoma: rare variant of intrahepatic cystic disease. South Med J (2000) 0.75
[Clinical evaluation of a new anorexigenic agent]. Rev Clin Esp (1970) 0.75
Further evolution of hepatitis C treatment: individualized therapy. Am J Gastroenterol (2000) 0.75
Finally: changing the natural history of chronic hepatitis C! Am J Gastroenterol (2001) 0.75
Diagnosis and treatment of chronic viral hepatitis. Compr Ther (1994) 0.75